Global Immunology Drugs Market to 2023 - Shifting Landscape as Uptake of Interleukin Receptor Inhibitors Offsets Losses for Top Blockbuster Drugs

  • ID: 4531929
  • Report
  • Region: Global
  • 181 Pages
  • GBI Research
1 of 5

FEATURED COMPANIES

  • AbbVie
  • Amgen
  • Celgene
  • Eli Lilly
  • Johnson & Johnson
  • Novartis
  • MORE

Immune-mediated inflammatory diseases are a common set of chronic disorders that affect 5-7% of people in Western populations. Although they are often disparate in terms of their symptoms and key patient demographics, they are pathophysiologically linked, being characterized by dysregulation of immune pathways and an inappropriate immune response. The following report covers all immunology disorders, with a particular focus on four key areas: rheumatoid arthritis (RA), psoriasis, inflammatory bowel disease (IBD) and transplant rejection/graft versus host disease (GVHD).

Immunology drugs market is projected to grow to $113 billion in 2023, at a compound annual growth rate (CAGR) of over 8%. The market size in the US is expected to increase at a CAGR of 6.58%, therefore accounting for approximately half of the global immunology market.

The prevalence populations of many indications within immunology are increasing, which is one of the major drivers of the expected market growth. For example, the prevalence population of RA across the seven major markets is expected to increase from 6.11 million in 2016 to 6.66 million in 2023.

Immunology market contains a number of blockbuster drugs, most of which are mAbs that target tumor necrosis alpha (TNF-a), a key pro-inflammatory cytokine. These include Humira (adalimumab), the most successful drug industry-wide, as well as Remicade (infliximab), Rituxan (rituximab), Simponi (golimumab) and Cimzia (certolizumab pegol). However, due to several recent and upcoming patent expiries, this drug class will suffer from biosimilar erosion over the forecast period, resulting in revenue decline and reduced dominance.

The first TNF biosimilars were approved several years ago when the first patents expired, but they are only now starting to have an impact on the revenue of their premium counterparts. For example, Remsima and Inflectra are Remicade biosimilars that have been approved in the EU, and Inflectra also has FDA approval to be marketed in 2018 when the patent for Remicade expires in the US. These biosimilars are exerting a very noticeable impact on Remicade’s revenue, which peaked in 2014 at $9.9 billion but is expected to fall to $3 billion by 2023.

Furthermore, there are also several drugs that have recently been approved - such as Cosentyx and Otezla - and several in late-stage pipeline development - such as, filgotinib, AR-101 and upadacitinib tartrate - that are expected to become blockbuster drugs over the forecast period, generating further market growth within immunology.

The report "Global Immunology Drugs Market to 2023 - Shifting Landscape as Uptake of Interleukin Receptor Inhibitors Offsets Losses for Top Blockbuster Drugs" provides the following -

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis for the four key indications.
  • Visualize the composition of the immunology market overall and across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players.
  • Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various immunological conditions.
  • Identify trends and developments, in terms of molecule type and molecular target, within the overall immunology pipeline, as well as for each of the four key indications.
  • Understand the growth in patient epidemiology and market revenues for the dermatology market globally, and across the key players and product types.
  • Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates, by stage of development, key indication, molecule type and molecular target.
  • Recognize how the evolving treatment landscape will drive market growth to 2023 and understand the contributions that different products, molecular targets and companies will make to this growth.
  • Identify commercial opportunities in the immunology deals landscape by analyzing trends in licensing and co-development deals.

Scope

  • The immunology market landscape is expected to change. Biosimilar competition is expected to affect the revenue of the big blockbuster drugs, and novel targets are expected to enter the market and drive market growth.
  • Overall, there are 2,070 immunology products in the pipeline.
  • Which molecular targets are most prominent within the pipeline?
  • How do the key indications differ in terms of molecule type?
  • How does the composition of the pipeline compare with that of the existing market?
  • What mechanisms of action are most common for pipeline drugs?
  • The market size for immunology therapeutics is expected to grow, from $65.1 billion in 2016 to $113 billion in 2023, at a CAGR of 8.2%.
  • Which products will contribute to market growth most, and which will achieve blockbuster status?
  • Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the dermatology market set to change?
  • What CAGR will these companies register in the forecast period?
  • How many strategic consolidations have been completed in the past decade?
  • Which types of assets attract the largest deal values?

Reasons to buy

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis for the four key indications.
  • Visualize the composition of the immunology market overall and across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players.
  • Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various immunological conditions.
  • Identify trends and developments, in terms of molecule type and molecular target, within the overall immunology pipeline, as well as for each of the four key indications.
  • Understand the growth in patient epidemiology and market revenues for the dermatology market globally, and across the key players and product types.
  • Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates, by stage of development, key indication, molecule type and molecular target.
  • Recognize how the evolving treatment landscape will drive market growth to 2023 and understand the contributions that different products, molecular targets and companies will make to this growth.
  • Identify commercial opportunities in the immunology deals landscape by analyzing trends in licensing and co-development deals.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie
  • Amgen
  • Celgene
  • Eli Lilly
  • Johnson & Johnson
  • Novartis
  • MORE

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Therapy Area Overview
2.1.1 Rheumatoid Arthritis
2.1.2 Psoriasis
2.1.3 Inflammatory Bowel Disease
2.1.4 Graft Versus Host Disease and Transplant Rejection
2.2 Symptoms
2.3 Diagnosis
2.3.1 Rheumatoid Arthritis
2.3.2 Psoriasis
2.3.3 Inflammatory Bowel Disease
2.3.4 Graft Versus Host Disease and Transplant Rejection
2.4 Etiology and Pathophysiology
2.4.1 Rheumatoid Arthritis
2.4.2 Psoriasis
2.4.3 Inflammatory Bowel Disease
2.4.4 Graft Versus Host Disease and Transplant Rejection
2.5 Epidemiology
2.5.1 Rheumatoid Arthritis
2.5.2 Psoriasis
2.5.3 Inflammatory Bowel Disease
2.5.4 Graft Versus Host Disease and Transplant Rejection
2.6 Co-morbidities and Complications
2.7 Treatment
2.7.1 Rheumatoid Arthritis
2.7.2 Psoriasis
2.7.3 Inflammatory Bowel Disease
2.7.4 Graft-Versus-Host Disease and Transplant Rejection

3 Key Marketed Products
3.1 Overview
3.2 Humira (adalimumab) - AbbVie
3.3 Enbrel (etanercept) - Amgen
3.4 Remicade (infliximab) - Johnson & Johnson
3.5 Rituxan (rituximab) - Roche
3.6 Stelara (ustekinumab) - Johnson & Johnson
3.7 Simponi (golimumab) - Johnson & Johnson
3.8 Orencia (abatacept) - Bristol-Myers Squibb
3.9 Tysabri (natalizumab) - Biogen
3.10 Actemra (tocilizumab) - Roche
3.11 Prograf (tacrolimus) - Astellas
3.12 Cimzia (certolizumab) - UCB
3.13 Entyvio (vedolizumab) - Takeda
3.14 Cosentyx (secukinumab) - Novartis
3.15 Otezla (apremilast) - Celgene
3.16 Xeljanz (tofacitinib) - Pfizer
3.17 Taltz (ixekizumab) - Eli Lilly

4 Pipeline Landscape Assessment
4.1 Overview
4.2 Pipeline Development Landscape
4.3 Molecular Targets in the Pipeline
4.4 Clinical Trials Landscape
4.4.1 Clinical Trial Failure Rates
4.4.2 Clinical Trial Duration
4.4.3 Clinical Trial Size
4.4.4 Cumulative Clinical Program Size
4.5 Assessment of Key Late-Stage Pipeline Products
4.5.1 Filgotinib - Galapagos and Gilead Sciences
4.5.2 AR-101 - Aimmune Therapeutics
4.5.3 Upadacitinib tartrate - AbbVie
4.5.4 Lanadelumab - Shire
4.5.5 Ozanimod hydrochloride - Celgene
4.5.6 Risankizumab - AbbVie
4.6 Conclusion

5 Multi-scenario Market Forecast to 2023
5.1 Overall Market Size
5.2 Generic Penetration
5.3 Revenue Forecast by Molecular Target
5.3.1 Cytokines and Cytokine Receptors
5.3.2 Intracellular Signal Transducers
5.3.3 Cell Surface Antigens
5.3.4 Intercellular Interaction and Adhesion Molecules

6 Company Analysis and Positioning
6.1 Revenue and Market Share Analysis by Company
6.1.1 AbbVie
6.1.2 Johnson & Johnson
6.1.3 Novartis
6.1.4 Pfizer
6.1.5 Roche
6.1.6 Amgen
6.1.7 Celgene
6.1.8 Eli Lilly
6.2 Company Landscape
6.3 Marketed and Pipeline Portfolio Analysis

7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deals by Region, Year and Value
7.1.2 Deals by Indication
7.1.3 Deals by Stage of Development
7.1.4 Deals by Molecule Type, Molecular Target and Value
7.1.5 Table for Licensing Deals with Disclosed Values
7.2 Co-development Deals
7.2.1 Deals by Region, Year and Value
7.2.2 Deals by Indication
7.2.3 Deals by Stage of Development
7.2.4 Deals by Molecule Type, Molecular Target and Value
7.2.5 Table for Co-development Deals with Disclosed Values

8 Appendix
8.1 References
8.2 Figures of All Clinical Stage Pipeline Products
8.3 Abbreviations
8.4 Disease List
8.5 Methodology
8.5.1 Coverage
8.5.2 Secondary Research
8.5.3 Market Size and Revenue Forecasts
8.5.4 Pipeline Analysis
8.5.5 Competitive Landscape
8.6 Contact Us
8.7 Disclaimer

List of Tables:
Table 1: Immunology Drugs Market, Global, Symptoms of RA, Psoriasis and IBD, 2018
Table 2: Immunology Drugs Market, Global, Organ-Specific Symptoms of Transplant Rejection, 2018
Table 3: Immunology Drugs Market, Global, Organ-Specific Symptoms of Acute GVHD, 2018
Table 4: Immunology Drugs Market, Global, Organ-Specific Symptoms of Chronic GVHD, 2018
Table 5: Immunology Drugs Market, Etiology of RA, Psoriasis, IBD and GVHD, 2018
Table 6: Immunology Drugs Market, 7MM, Epidemiology of Key Immunology Indications, 2018
Table 7: Immunology Drugs Market, Global, Approved Indications for Humira, 2018
Table 8: Immunology Drugs Market, Global, Approved Indications for Enbrel, 2018
Table 9: Immunology Drugs Market, Global, Approved Indications for Remicade, 2018
Table 10: Immunology Drugs Market, Global, Approved Indications for Rituxan, 2018
Table 11: Immunology Drugs Market, Global, Approved Indications for Stelara, 2018
Table 12: Immunology Drugs Market, Global, Approved Indications for Simponi, 2018
Table 13: Immunology Drugs Market, Global, Approved Indications for Orencia, 2018
Table 14: Immunology Drugs Market, Global, Approved Indications for Tysabri, 2018
Table 15: Immunology Drugs Market, Global, Approved Indications for Actemra, 2018
Table 16: Immunology Drugs Market, Global, Approved Indications for Prograf, 2018
Table 17: Immunology Drugs Market, Global, Approved Indications for Cimzia, 2018
Table 18: Immunology Drugs Market, Global, Approved Indications for Entyvio, 2018
Table 19: Immunology Drugs Market, Global, Approved Indications for Cosentyx, 2018
Table 20: Immunology Drugs Market, Global, Approved Indications for Otezla, 2018
Table 21: Immunology Drugs Market, Global, Approved Indications for Xeljanz, 2018
Table 22: Immunology Drugs Market, Global, Approved Indications for Taltz, 2018
Table 23: Immunology Drugs Market, Global, Annual Revenue Forecast for Key Products ($m), 2016-2023
Table 24: Immunology Drugs Market, Global, Usage of Generics Across Key Indications, 2018
Table 25: Immunology Drugs Market, Global, Forecast Revenue by Company (%), 2016-2023

List of Figures:
Figure 1: Immunology Drugs Market, 7MM, Epidemiology Patterns for Rheumatoid Arthritis, 2016-2023
Figure 2: Immunology Drugs Market, 7MM, Epidemiology Patterns for Psoriasis, 2016-2023
Figure 3: Immunology Drugs Market, 7MM, Epidemiology Patterns for Crohn’s Disease, 2016-2023
Figure 4: Immunology Drugs Market, Epidemiology Patterns for Ulcerative colitis, 2016-2023
Figure 5: Immunology Drugs Market, Epidemiology Patterns for Graft Versus Host Disease, 2016-2023
Figure 6: Immunology Drugs Market, Global, Key Marketed Products and Approved Indications, 2018
Figure 7: Immunology Drugs Market, Global, Annual Revenues for Humira ($bn), 2006-2023
Figure 8: Immunology Drugs Market, Global, Annual Revenue for Enbrel ($bn), 2006-2023
Figure 9: Immunology Drugs Market, Global, Annual Revenue for Remicade ($bn), 2006-2023
Figure 10: Immunology Drugs Market, Global, Annual Revenue for Rituxan ($bn), 2006-2023
Figure 11: Immunology Therapeutics Market, Global, Annual Revenue for Stelara ($bn), 2010-2023
Figure 12: Immunology Drugs Market, Global, Annual Revenue for Simponi ($bn), 2010-2023
Figure 13: Immunology Drugs Market, Global, Annual Revenue for Orencia ($bn), 2006-2023
Figure 14: Immunology Drugs Market, Global, Annual Revenue for Tysabri ($bn), 2006-2023
Figure 15: Immunology Drugs Market, Global, Annual Revenues for Actemra ($bn), 2006-2023
Figure 16: Immunology Drugs Market, Global, Annual Revenue for Prograf ($bn), 2006-2023
Figure 17: Immunology Drugs Market, Global, Annual Revenue for Cimzia ($bn), 2008-2023
Figure 18: Immunology Drugs Market, Global, Annual Revenue for Entyvio ($bn), 2014-2023
Figure 19: Immunology Drugs Market, Global, Annual Revenue for Cosentyx ($bn), 2015-2023
Figure 20: Immunology Drugs Market, Global, Annual Revenue for Otezla($bn), 2014-2023
Figure 21: Immunology Drugs Market, Global, Annual Revenues for Xeljanz ($bn), 2012-2023
Figure 22: Immunology Drugs Market, Global, Annual Revenue for Taltz ($bn), 2016-2023
Figure 23: Immunology Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018
Figure 24: Immunology Drugs Market, Global, Pipeline by Stage of Development and Molecule Type, 2018
Figure 25: Immunology Drugs Market, Global, Pipeline by Program Type, 2018
Figure 26: Immunology Drugs Market, Global, Pipeline for Key Immunology Indications by Stage of Development, 2018
Figure 27: Immunology Drugs Market, Global, Pipeline for Key Immunology Indications by Molecule Type, 2018
Figure 28: Immunology Drugs Market, Pipeline by Molecular Target, 2018
Figure 29: Immunology Drugs Market, Global, Pipeline for Key Immunology Indications by Molecular Target, 2018
Figure 30: Immunology Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rate by Stage of Development (%), 2006-2018
Figure 31: Immunology Drugs Market, Global, Clinical Trial Failure Rates by Key Indication and Stage of Development (%), 2006-2017
Figure 32: Immunology Drugs Market, Global, Clinical Trial Failure Rates by Molecule Type and Stage of Development (%), 2006-2017
Figure 33: Immunology Drugs Market, Global, Clinical Trial Failure Rates by Molecular Target and Stage of Development (%), 2006-2017
Figure 34: Immunology Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2017
Figure 35: Immunology Drugs Market, Global, Clinical Trial Duration by Key Indication and Stage of Development (months), 2006-2017
Figure 36: Immunology Drugs Market, Global, Clinical Trial Duration by Molecule Type and Stage of Development (months), 2006-2017
Figure 37: Immunology Drugs Market, Global, Clinical Trial Duration by Molecular Target and Stage of Development (months), 2006-2017
Figure 38: Immunology Drugs Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2017
Figure 39: Immunology Drugs Market, Global, Clinical Trial Size by Key Indication and Stage of Development (participants), 2006-2017
Figure 40: Immunology Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2017
Figure 41: Immunology Drugs Market, Global, Clinical Trial Size by Molecular Target and Stage of Development (participants), 2006-2017
Figure 42: Immunology Drugs Market, Global, Clinical Program Size by Stage of Development (participants), 2006-2017
Figure 43: Immunology Drugs Market, Global, Clinical Program Size by Key Indication and Stage of Development (participants), 2006-2017
Figure 44: Immunology Drugs Market, Global, Clinical Program Size by Molecule Type and Stage of Development (participants), 2006-2017
Figure 45: Immunology Drugs Market, Global, Clinical Program Size by Molecular Target and Stage of Development (participants), 2006-2017
Figure 46: Immunology Drugs Market, Global, Annual Revenue Forecast for Filgotinib ($m), 2019-2023
Figure 47: Immunology Drugs Market, Global, Annual Revenue Forecast for AR-101 ($m), 2019-2023
Figure 48: Immunology Drugs Market, Global, Annual Revenue Forecast for Upadacitinib ($m), 2019-2023
Figure 49: Immunology, Global, Annual Revenue Forecast for Lanadelumab ($m), 2018-2023
Figure 50: Immunology Drugs Market, Global, Annual Revenue Forecast for Ozanimod ($m), 2018-2023
Figure 51: Immunology Drugs Market, Global, Annual Revenue Forecast for Risankizumab ($m), 2018-2023
Figure 52: Immunology Drugs Market, Global, Market Size ($bn), 2016-2023
Figure 53: Immunology Drugs Market, Global, Annual Revenue Forecast for Premium and Generic Products ($bn), 2016-2023
Figure 54: Immunology Drugs Market, Global, Annual Revenue Forecast for Cytokines and Cytokine Receptors ($bn), 2016-2023
Figure 55: Immunology Drugs Market, Global, Annual Revenue Forecast for Intracellular Signal Transducers ($bn), 2016-2023
Figure 56: Immunology Drugs Market, Global, Annual Revenue Forecast for Cell Surface Antigens ($bn), 2016-2023
Figure 57: Immunology Drugs Market, Global, Annual Revenue Forecast for Intercellular Interaction and Adhesion Molecules ($bn), 2016-2023
Figure 58: Immunology Drugs Market, Global, Company Analysis Matrix, 2016-2023
Figure 59: Immunology Drugs Market, Global, Cluster by Growth and Market Share, 2016-2023
Figure 60: Immunology Drugs Market, Global, Forecast Market Share by Company (%), 2016-2023
Figure 61: Immunology Drugs Market, Global, Companies by Compound Annual Growth Rate (%), 2016-2023
Figure 62: Immunology Drugs Market, Global, Revenues by Route of Acquisition, 2016-2023
Figure 63: Immunology Drugs Market, Global, AbbVie, Annual Revenue Forecast ($bn), 2016-2023
Figure 64: Immunology Drugs Market, Global, Johnson & Johnson, Annual Revenue Forecast ($bn), 2016-2023
Figure 65: Immunology Drugs Market, Global, Novartis Annual Revenue Forecast ($bn), 2016-2023
Figure 66: Immunology Drugs Market, Global, Pfizer, Annual Revenue Forecast ($bn), 2016-2023
Figure 67: Immunology Drugs Market, Global, Roche Annual Revenue Forecast ($bn), 2016-2023
Figure 68: Immunology Drugs Market, Global, Amgen, Annual Revenue Forecast ($bn), 2016-2023
Figure 69: Immunology Drugs Market, Global, Celgene, Annual Revenue Forecast ($bn), 2016-2023
Figure 70: Immunology Drugs Market, Global, Eli Lilly, Annual Revenue Forecast ($bn), 2016-2023
Figure 71: Immunology Drugs Market, Global, High-Activity and Late-Stage Pipeline Developers by Company Type, 2018
Figure 72: Immunology Drugs Market, Global, Pipeline, High-Activity and Late-Stage Pipeline Developers by Level of Specialization, 2018

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • Roche
  • Amgen
  • Celgene
  • Eli Lilly
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll